Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days
Dyadic developed stable C1 cell lines and produced Bundibugyo ebolavirus antigens in approximately 15 days, delivering them to Scripps Research and FBS for preclinical evaluation. The rapid production cycle highlights the C1 platform's potential to address active outbreaks where no approved treatments exist, emphasizing speed and scalability.
Key figures
- Gates grant usd
- 3100000
- Production time days
- 15
- Antibody titer g per l
- 12
- Titer production time days
- 7
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.